Fundz

Who to call at Edity Therapeutics, and when

Fundz watches for the moments Edity Therapeutics starts buying, and tells you who to reach.

  • An alert the day Edity Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Edity Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Edity Therapeutics and Aurigene Oncology Enter Strategic Co-Development Partnership for Novel Cell Therapy Program for Solid Tumors

Apr 03, 2025

Contract Type

partnership

IsraelBiotechnologyHealth CareTherapeutics

Description

Edity Therapeutics Limited and Aurigene Oncology Limited have announced a strategic collaboration to develop novel cell therapy medicines for difficult-to-treat solid tumors. The partnership is supported by government grants and aims to co-develop the first joint program for solid tumors.

Company Information

Company

Edity Therapeutics

Location

Israel

About

Edity Therapeutics is headquartered in Israel and is focused on the development of advanced immune cell delivery platforms, with product candidates across the fields of oncology, gene therapy, autoimmune disorders, and regenerative medicine. The company has been addressing the challenges of cell therapies for solid tumors, including antigen heterogeneity, the immunosuppressive tumor microenvironment, and tumor resistance to death.

Predictive Intelligence
Strategic

ML-powered predictions for Edity Therapeutics's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Edity Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.